Bio-Techne Corp (TECH)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$48.51
Buy
$49.21
$-0.76 (-1.56%)
Prices updated at 28 May 2025, 23:26 EDT
| Prices minimum 15 mins delay
Prices in USD
Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Robert V. Baumgartner, C.P.A.
CEO
Mr. Kim Kelderman
Most recent earnings
30 Jun 2024
Fiscal year end
30 Jun 2024
Employees
3,100
Head office
614 McKinley Place N.E.
Minneapolis
United States
55413
Key personnel
Owner name | Salary |
---|---|
Dr. Roeland Nusse,PhD Independent Director | 0.09m |
Dr. Amy Herr, PhD Independent Director | - |
Mr. John L. Higgins Independent Director | 0.10m |
Dr. Joseph D. Keegan, PhD Independent Director | 0.08m |
Mr. Robert V. Baumgartner, C.P.A. Chairman of the Board | 0.21m |
Ms. Julie L. Bushman Independent Director | 0.09m |
Mr. James T. Hippel Principal Accounting Officer, Executive Vice President and Chief Financial Officer | 0.70m |
Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A. Independent Director | 0.08m |
Dr. Alpna Seth, PhD Independent Director | 0.08m |
Mr. Kim Kelderman President, Chief Executive Officer and Director | 0.76m |
Dr. Judith Klimovsky, M.D. Independent Director | 0.01m |
Mr. William Geist President, Protein Sciences | 0.55m |
Dr. Matthew McManus President, Diagnostics and Genomics Segment | 0.25m |
Mr. Shane Bohnen Senior Vice President, General Counsel and Corporate Secretary | 0.34m |
Top 5 shareholders
Owner name | No. of shares |
---|---|
Vanguard Group Inc | 18,526,824 |
BlackRock Inc | 13,746,351 |
BlackRock, Inc. | 13,843,281 |
T. Rowe Price Associates, Inc. | 11,375,279 |
T Rowe Price Associates, Inc | 9,424,313 |
Director dealings
Date | Action |
---|---|
01 Nov 2024 | - |
01 Nov 2024 | - |
01 Nov 2024 | - |
01 Nov 2024 | - |
01 Nov 2024 | - |
01 Nov 2024 | - |
01 Nov 2024 | - |
01 Nov 2024 | - |
24 Oct 2024 | - |
24 Oct 2024 | - |
24 Oct 2024 | - |
24 Oct 2024 | - |
24 Oct 2024 | - |
24 Oct 2024 | - |
24 Oct 2024 | - |
24 Oct 2024 | - |
24 Oct 2024 | - |
24 Oct 2024 | - |
24 Oct 2024 | - |
24 Oct 2024 | - |
Please note that past performance is not a reliable indicator of future returns.